Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.40 USD
Change Today +0.033 / 2.41%
Volume 1.8K
OGEN On Other Exchanges
As of 5:15 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

oragenics inc (OGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/6/15 - $3.87
52 Week Low
06/2/15 - $0.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ORAGENICS INC (OGEN)

Related News

No related news articles were found.

oragenics inc (OGEN) Related Businessweek News

No Related Businessweek News Found

oragenics inc (OGEN) Details

Oragenics, Inc. develops, markets, and sells oral probiotics products and antibiotics for humans and companion pets. The company develops and markets probiotic products comprising ProBiora3, ProBiora3, a blend of oral care probiotics that promote fresher breath, whiter teeth, and support oral health under the Evora and ProBiora brands. Its ProBiora3 products include flavored probiotic tablets, such as EvoraPlus and EvoraKids for daily use by adults and children; EvoraPet for companion pets, including cats and dogs; and EvoraPro, a product for the dental office channel. The company’s products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay; and MU1140 and other homolog antibiotic products. The company markets and sells its products through direct-to-consumer channels, professional offices, and private label partnerships. It has collaboration agreement with Intrexon Corporation for the development and commercialization of the native strain of MU1140 and related homologs. The company, formerly known as Oragen, Inc., was founded in 1996 and is headquartered in Tampa, Florida.

12 Employees
Last Reported Date: 02/27/15
Founded in 1996

oragenics inc (OGEN) Top Compensated Officers

Interim Principal Executive Officer, Chief Fi...
Total Annual Compensation: $220.7K
Senior Vice President of Operations & Product...
Total Annual Compensation: $188.9K
Senior Vice President of Discovery Research
Total Annual Compensation: $194.1K
Compensation as of Fiscal Year 2014.

oragenics inc (OGEN) Key Developments

Oragenics, Inc. and Intrexon Corporation Mutually Agreed to Terminate the Exclusive Channel Collaboration Agreement

On September 30, 2015, Oragenics Inc. and Intrexon Corporation mutually agreed to terminate the Exclusive Channel Collaboration Agreement dated September 30, 2013 regarding the development and commercialization of probiotics (the Live Biotherapeutic Products ECC). Oragenics' other two Exclusive Channel Collaboration Agreements with Intrexon regarding lantibiotics and oral mucositis will continue in full force and effect notwithstanding the termination of the Live Biotherapeutic Products ECC. The termination of the Live Biotherapeutic Products ECC was to enable Oragenics to focus its resources on the lantibiotic and oral mucositis programs.

Oragenics Inc. Reports Positive Results of an Independent ProBiora3 Study

Oragenics Inc. announced the completion of an independent study evaluating the effects of a chewable tablet containing ProBiora3, in early childhood development of dental caries in preschool children living in low socioeconomic, multicultural areas. The study employed a randomized double-blind placebo-controlled design consisting of 138 healthy children ranging from two to three years in age. The children were placed into groups that were administered once a day either chewable tablets containing ProBiora3 or a placebo tablet. In conjunction with this study, parents were further instructed to thoroughly brush the children's teeth in each group twice daily with fluoride toothpaste. Study duration was one year with 66% compliance. Overall, the ProBiora3 administered group observed statistically significant lower dental caries increments than in the placebo group, 0.2 vs. 0.8 (p<0.05). The risk reduction for caries development was 0.47 (95% CI 0.24-0.98), with no side effects being reported among either group.

Oragenics, Inc. Reports Positive in Vivo Antibiotic Efficacy Data in Critical Animal Study

Oragenics Inc. and Intrexon Corporation announced positive data on multiple compounds from Oragenics’ Mutacin 1140 (MU1140) lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate. The compounds were subjected to a standardized ‘proof of concept’ animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomycin positive control. Lantibiotics are a class of antibiotics with a novel mechanism of action active against several multi-drug resistant infectious agents. Through its Exclusive Channel Collaboration (ECC), Oragenics has utilized Intrexon’s proprietary bio-engineering capabilities to develop its MU1140 analog pipeline which could provide an important new tool in the fight against global bacterial antibiotic resistance. The tested compounds were selected based on important compound characteristics including, but not limited to: drug activity (based on minimum inhibitory concentration) equal or better than ‘standard of care’ drugs against certain drug-resistant bacteria, safety, toxicity, stability, and manufacturability. The study specifically evaluated compound efficacy as measured by survivability, amounts of C. difficile colony forming units, and toxin levels. Overall several compounds demonstrated promising results, and Oragenics’ new lead clinical candidate achieved a 100% survival rate throughout the entire study in contrast to a 33% survival rate for the vancomycin (current standard of care) positive control. There was a 0% survival rate for the placebo control group.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGEN:US $1.40 USD +0.033

OGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioGaia AB kr284.50 SEK +1.00
BLIS Technologies Ltd $0.03 NZD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 44.1x
Price/Book 34.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 33.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact ORAGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at